Monday, Aug 24, 1987
South San Francisco, Calif. -- August 24, 1987 --Genentech, Inc. (NASDAQ:GENE) has begun litigation against Toyobo Co., Ltd. and its subsidiary, K.K. Toyobo Biotech, charging infringement of the company's patent claims for recombinant tissue plasminogen activator (t-PA). The company's complaint was filed August 20 in Osaka District Court in Japan.
Recombinant t-PA, first produced by Genentech in 1982 and already approved for sale in Austria, France, New Zealand and the Philippines, is a thrombolytic or clot-dissolving agent for use in the treatment of myocardial infarction (heart attack) and other blood-clot related diseases.
According to Robert A. Swanson, chief executive officer of Genentech, "The action against Toyobo is aimed at protecting the interests of our licensees in Japan and consistent with our belief that our t-PA patent rights are valid and enforceable." Genentech has licensed Mitsubishi Chemical Industries Limited and Kyowa Hakko Kogyo Co., Ltd. to develop and market t-PA in Japan.
Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #